Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2002

View Archived Issues

Drug pipeline for sleep disorders

Several related series of antidepressants under development at Wyeth

Celltech presents novel receptor tyrosine kinase inhibitors for cancer, psoriasis, etc.

Aventis claims CDK2 inhibitors for cancer and chemotherapy-induced neuronal apoptosis

Novel glucocorticoids in early development at GSK

Aventis discovers antiarrhythmic Kv1.5 channel blockers

New inhibitors of fatty acid amide hydrolase with utility in neuropathic pain

Vertex describes the preparation and use of novel beta-secretase inhibitors

Promising toxicity and antitumor efficacy for temozolomide + vatalanib succinate in glioblastoma

Potential use of TP-38 in recurrent malignant brain tumors

Improved survival rate found with 131I-ch81C6 in malignant brain tumors

SU-11248: preclinical and early clinical findings encourage further development

Telomerase inhibitor with potential as an antitumor and radiosensitizing agent

Sulfonyhydrazine prodrug VNP-40101M advances towards phase II clinical evaluation

Corixa withdraws dispute resolution as FDA returns Bexxar to active review status

Human Genome Sciences and Kirin announce license agreement

Taxotere approved for first-line therapy in NSCLC

Lexapro oral solution provides new option for depressed patients

Approvable letter for Pennsaid in Canada

Axcan receives approvable letter for Photofrin

Enrollment completed in phase III trial of ABI-007

Genetronics and Chiron extend collaboration to test HIV vaccine delivery

Mercury Therapeutics licenses oncology target from Mass General

Milestone reached in Mercury Therapeutics and Aventis AMPK collaboration

Antibody product enters phase I for autoimmune disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...